e=Bone™, an absorbent bone regeneration material, is launched by a consolidated subsidiary.
2023.03.30 New products
The purpose of this news release is to inform our stakeholders about our corporate activities. While it may contain information about our products and research and development, it is not intended to be a promotion, advertisement, or medical advice regarding our products. The information contained herein is current as of the date of publication. Please note that the information is subject to change without prior notice.
Bando Chemical Industries, LTD. (Headquarters: Kobe, Hyogo, Japan; URL: https://www.), a consolidated subsidiary of Bando Chemical Industries, LTD., Aimedic MMT CO., LTD., in collaboration with the Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, and the Department of Materials Production Science, Osaka University Graduate School of Engineering, have launched a joint research project on the development of artificial bones. The research results obtained in this project have been used to develop an absorbable bone regeneration material, "e=Bone™ We are pleased to announce that we will be selling "eBorn™" (eBorn) from April 1, 2023.
1. Product Overview
2. Background and Aims of Development
Currently, autologous bone grafting (harvesting and transplanting the patient's own bone), artificial bone grafting, or bone grafting using a combination of autologous and artificial bone are commonly used as therapies for bone defects in Japan. Although autologous bone grafting accounts for about half of all bone grafting procedures in Japan, complications such as pain and infection at the bone grafting site, extreme difficulty in obtaining good quality bone for elderly patients with osteoporosis, and increased physical and psychological burden due to the limited amount of bone that can be extracted are problems. On the other hand, in the case of artificial bone grafting On the other hand, in the case of artificial bone grafts, although there is no limit to the amount of bone that can be harvested, the existing artificial bone does not promote bone formation, so it takes time for the bone to "fuse" with the patient's bone, causing limitation of movement, delay in return to social activities and ADL (*1), and these problems are a cause of social loss.
Aimedic MMT CO., LTD. has launched an epoch-making research project for the development of artificial bones by modifying the surface of artificial bones with plasma treatment to give them osteogenic activity, as an industry-academia joint research project with a research group led by Associate Professor Takashi Kaiwatari of the Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, and Professor Satoshi Hamaguchi of the Department of Materials Production Science, Osaka University Graduate School of Engineering. The project was launched as an industry-academia joint research project with a research group led by Associate Professor Takashi Kaiwatari of the Osaka University Graduate School of Medicine and Professor Satoshi Hamaguchi of the Osaka University Graduate School of Engineering's Department of Materials Production Science.
In Japan, where the super-aging population is accelerating, shortening the duration of treatment is an urgent issue. If artificial bones that promote bone formation can be developed, early bone fusion will be possible, enabling rehabilitation to begin at an early stage, improving ADL and QOL (*2) by ensuring early recovery of walking ability, and contributing to shortening the time until return to work. 2) and shorten the time to return to work. At the same time, the system is expected to contribute to securing medical resources by reducing the burden of nursing care on medical personnel and their families and reducing overall medical costs.
3. New Product Features
Nitrogen, a component of amino groups, is modified on the surface of artificial bone, which has a porous structure with a series of small cavities. Amino groups are used to improve the surface of petri dishes for cell culture, and have been proven to improve cell adhesion. The amino group nitrogen modified on the surface of the product is expected to promote cell adhesion, osteoblast differentiation, and bone formation after implantation, allowing the biological tissue to quickly penetrate deep into the artificial bone and be absorbed or replaced while ensuring sufficient strength in the bone healing process.
(*1) ADL: Activities of Daily Living
(*2) Quality of Life (QOL)
... and upwards
The information on this page is current as of the date of publication, and may be different from the information available at the time of your visit. Please be aware that the information may differ from the information on this page at the time of your visit.